MedXCell SA

Ultimate Medicine AG, a Swiss preclinical pharmaceutical company, is developing an innovative oral treatment for age-related cognitive disorders. Our approach targets an overlooked pathway complementing standard amyloid-β/tau therapies.

TheraPPI Bioscience, a preclinical biotechnology company developing small molecules modifying protein interactions in oncology, rare diseases and inflammation

The Future Rewritten: Unlocking Genome Editing. By fusing directed evolution, high-throughput characterization, and AI, Nerai creates novel CRISPR editors, more precise and more powerful, making gene editing safer and accessible to more patients.